Achaogen (AKAO) PT Raised to $25 at William Blair
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Achaogen Announces Positive Results in Phase 3 cUTI and CRE Clinical Trials of Plazomicin
December 12, 2016 7:00 AM EST-- EPIC registration trial successfully achieves FDA primary endpoints in patients with complicated urinary tract infections (cUTI) --
-- EPIC demonstrates superiority on EMA primary endpoints --
-- CARE descriptive trial shows 71 percent relative reduction in Day 28 all-cause mortality compared with colistin in patients with serious CRE infections --
-- Plazomicin well tolerated in both trials and shows improved overall safety compared with colistin in CARE trial --
-- Company plans to... More
